並列摘要
Dementia is a syndrome that seizes human memory and cognitive function, including cognitive abnormality, degeneration of memory, and the emergence of psychosis. Past studies have shown that individuals at all stages of chronic kidney disease (CKD) have a higher risk of developing cognitive disorders such as dementia. Besides, erythropoietin and iron are indicated to treat anemia in patients with CKD and end-stage renal disease. Erythropoietin is known to have neuroprotective effects and is correlated with improved cognitive functions. Interestingly, the use of erythropoietin medications in hemodialysis patients is associated with a reduced risk of vascular dementia and unspecified dementia. Thus, erythropoietin may have the opportunity to develop into a therapeutic drug for vascular dementia, and more research is needed.